NCT03688568 is a Phase 2 clinical trial of Imatinib Mesylate in Neurofibroma, Plexiform, sponsored by Indiana University.

Who is sponsoring NCT03688568?

NCT03688568 is sponsored by Indiana University.

What drugs are being tested in NCT03688568?

Interventions in NCT03688568: Imatinib Mesylate.

What condition does NCT03688568 study?

NCT03688568 studies Neurofibroma, Plexiform.

Is NCT03688568 still recruiting?

NCT03688568 is currently withdrawn. Last updated 12 February 2021.

Last reviewed 2021-02-12 · How we verify

NCT03688568

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Withdrawn Phase 2 Last updated 12 February 2021

What this trial tests

Phase 2 trial testing Imatinib Mesylate in Neurofibroma, Plexiform. Withdrawn.

Timeline

1 September 2018

Primary endpoint
1 September 2020

1 September 2021

Quick facts

Lead sponsor	Indiana University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 September 2018
Primary completion	1 September 2020
Estimated completion	1 September 2021
Sites	1 location across United States

Drugs / interventions tested

Imatinib Mesylate — full drug profile →

Conditions studied

Neurofibroma, Plexiform — all drugs for Neurofibroma, Plexiform →

Sponsor

Indiana University

Who can join

Adults 6 Months to 12, any sex, with Neurofibroma, Plexiform. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R. · · 2021 · cited 153× · PMID 34072574 · DOI 10.3390/ijms22115850
Neurofibromatosis Type 1 and the Search for Effective Tumor Therapies Using High-Throughput Drug Screening.
Bouley SJ, Housden BE, Walker JA. · · 2025 · PMID 41294711 · DOI 10.3390/curroncol32110649

Verify or expand the search:

Other trials of Imatinib Mesylate

Trials testing the same drug.

NCT05970900 — Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST · Phase 3 · not yet recruiting
NCT05623774 — A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg · Phase 1 · completed
NCT05385549 — 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk · Phase 2 · recruiting
NCT04953052 — A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of A · Phase 2 · withdrawn
NCT04416750 — Positioning Imatinib for Pulmonary Arterial Hypertension · Phase 2 · unknown

Other recruiting trials for Neurofibroma, Plexiform

Currently open trials in the same condition.

NCT06360406 — Real-World Treatment Study of Koselugo (Selumetinib) · recruiting
NCT06175637 — Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs · active not recruiting
NCT05199376 — Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neu · NA · recruiting
NCT03741101 — Treatment of NF1-related Plexiform Neurofibroma With Trametinib · Phase 2 · active not recruiting
NCT02390752 — Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractor · Phase 1 · recruiting

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03688568 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 12 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03688568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing